Innate Pharma S.A. IDDA.MU Stock
Innate Pharma S.A. Price Chart
Innate Pharma S.A. IDDA.MU Financial and Trading Overview
Innate Pharma S.A. stock price | 2.34 EUR |
Previous Close | 3 EUR |
Open | 3 EUR |
Bid | 3 EUR x N/A |
Ask | 3.2 EUR x N/A |
Day's Range | 3 - 3 EUR |
52 Week Range | 2.18 - 3.6 EUR |
Volume | 800 EUR |
Avg. Volume | 14 EUR |
Market Cap | 259.05M EUR |
Beta (5Y Monthly) | 0.273946 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.09 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
IDDA.MU Valuation Measures
Enterprise Value | 179.74M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4.4916925 |
Price/Book (mrq) | 4.444444 |
Enterprise Value/Revenue | 3.117 |
Enterprise Value/EBITDA | -14.954 |
Trading Information
Innate Pharma S.A. Stock Price History
Beta (5Y Monthly) | 0.273946 |
52-Week Change | 20.00% |
S&P500 52-Week Change | 20.43% |
52 Week High | 3.6 EUR |
52 Week Low | 2.18 EUR |
50-Day Moving Average | 2.81 EUR |
200-Day Moving Average | 2.71 EUR |
IDDA.MU Share Statistics
Avg. Volume (3 month) | 14 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 80.46M |
Float | 30.1M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.50% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -100.74% |
Operating Margin (ttm) | -28.47% |
Gross Margin | 10.42% |
EBITDA Margin | -20.84% |
Management Effectiveness
Return on Assets (ttm) | -4.31% |
Return on Equity (ttm) | -71.75% |
Income Statement
Revenue (ttm) | 57.67M EUR |
Revenue Per Share (ttm) | 0.72 EUR |
Quarterly Revenue Growth (yoy) | 6.09% |
Gross Profit (ttm) | N/A |
EBITDA | -12020000 EUR |
Net Income Avi to Common (ttm) | -57972000 EUR |
Diluted EPS (ttm) | -0.73 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 101.49M EUR |
Total Cash Per Share (mrq) | 1.27 EUR |
Total Debt (mrq) | 42.25M EUR |
Total Debt/Equity (mrq) | 78.02 EUR |
Current Ratio (mrq) | 3.383 |
Book Value Per Share (mrq) | 0.675 |
Cash Flow Statement
Operating Cash Flow (ttm) | -19154000 EUR |
Levered Free Cash Flow (ttm) | -32741624 EUR |
Profile of Innate Pharma S.A.
Country | Germany |
State | N/A |
City | Marseille |
Address | 117, Avenue de Luminy |
ZIP | 13009 |
Phone | 33 4 30 30 30 30 |
Website | https://www.innate-pharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 211 |
Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH4501, an antibody drug conjugates (ADC); and IPH65, a tetra-specific proprietary antibody. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.
Q&A For Innate Pharma S.A. Stock
What is a current IDDA.MU stock price?
Innate Pharma S.A. IDDA.MU stock price today per share is 2.34 EUR.
How to purchase Innate Pharma S.A. stock?
You can buy IDDA.MU shares on the Munich exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Innate Pharma S.A.?
The stock symbol or ticker of Innate Pharma S.A. is IDDA.MU.
Which industry does the Innate Pharma S.A. company belong to?
The Innate Pharma S.A. industry is Biotechnology.
How many shares does Innate Pharma S.A. have in circulation?
The max supply of Innate Pharma S.A. shares is 80.84M.
What is Innate Pharma S.A. Price to Earnings Ratio (PE Ratio)?
Innate Pharma S.A. PE Ratio is now.
What was Innate Pharma S.A. earnings per share over the trailing 12 months (TTM)?
Innate Pharma S.A. EPS is -0.09 EUR over the trailing 12 months.
Which sector does the Innate Pharma S.A. company belong to?
The Innate Pharma S.A. sector is Healthcare.